» Gruźlica lekooporna w Polsce

*Ewa Augustynowicz-Kopeć, Zofia Zwolska

Gruźlica lekooporna w Polsce

Drug resistant tuberculosis in Poland

Zakład Mikrobiologii Instytutu Gruźlicy i Chorób Płuc, Warszawa
Kierownik Zakładu: prof. dr. hab. Zofia Zwolska

Summary

Key words:

Piśmiennictwo

1. Heymann SJ et al.: The need for global; action against multidrug-resistant tuberculosis. JAMA 1999; 281: 2138-2140. 2. Wilson ME: Travel and the emergence of infectious diseases. Emerg. Infect. Dis. 1995; 1: 39-46. 3. Dye C: Tuberculosis 2000-2010: Control, but not elimination. Int. J. Tuberc. Lung Dis. 2000; 4: S146-S152. 4. Migliori GB et al.: and the National AIPO Tuberculosis Study Group. Prospective multicentre study on the evaluation of anti-tuberculosis treatment results in Italy: comparison of the culture-versus the smear-based methods. Eur. Respir. J. 1999; 13: 900-903. 5. Migliori GB et al.: Prevalence of resistance to anti-tuberculosis drugs: results of the 1998/99 national survey in Italy. Int. J. Tuberc. Lung Dis. 2002; 6: 32-38. 6. Morris S et al.: Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J. Infect. Dis. 1995; 171: 954-960. 7. Telenti A: Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax 1998; 53: 793-797. 8. Drobner P et al.: Usefulness of Mycobacterium tuberculosis genomic mutations in the gene katG and inhA for the prediction of isoniazid resistance. Int. J. Tuberc. Lung Dis. 1997; 1: 365-369. 9. O´Brien KL et al.: Evaluation of inhA gene and catalase-peroxidase gene among isoniazid-sensitive and-resistant Mycobacterium tuberculosis isolates. Moll. Cell Probes 1996; 10: 1-6. 10. Rinder H et al.: Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis. 1998; 17: 508-511. 11. Telenti A et al.: Genotypic assessment of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J. Clin. Microbiol. 1997; 35: 719-723. 12. Matsiota-Bernard P, Vroni G, Marinis E: Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Greece. J. Clin. Microbiol. 1998; 36: 20-23. 13. Telenti A et al.: Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-650. 14. Geerligs WA et al.: Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int. J. Tuberc. Lung Dis. 2000; 4: 785-764. 15. Nations JA, Lazarus AA, Walsh TW: Drug-resistant tuberculosis. Dis. Mon. 2006; 52: 435-440. 16. Canetti G, Rist N, Grosset J: Primary drug resistance in tuberculosis. Am. Rev. Resp. Dis. 1964; 90: 792-799. 17. Clinical trial of 6-month and 4 month regiments of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 1981; 62(2): 95-102. 18. Robert J et al.: Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. Int. J. Tuberc. Lung Dis. 2000; 4: 665-672. 19. Snider DE et al.: Drug resistant tuberculosis. Am. Rev. Respir. Dis. 1991; 144: 732-732. 20. Fox W, Ellard GA, Mitchison DAL: Studies on the treatment of tuberculosis undertaken by the British medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 1999; 3: S231-S279.21. Cohn DL, Bustreo F, Raviglione MC: Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin. Infect. Dis. 1997; 24: Supl. 1. S121-S130. 22. Frieden TR et al.: The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 1993; 328: 521-526. 23. Janowiec M, Zwolska-Kwiek Z: Pierwotna oporność na leki przeciwprątkowe u chorych na gručlicę w Polsce w latach 1978-1982. Pneumonol. Pol. 1986; 54: 140-143. 24. Janowiec M, Zwolska-Kwiek Z, Bek E: Drug resistance in newly discovered untreated tuberculosis patients in Poland 1974-1977. Tubercle 1979; 60: 233-237. 25. Hornung S, Polończyk M: Pierwotna oporność na podstawowe leki u chorych na gručlicę płuc. Gručlica 1962; 30: 349-358. 26. Zierski M: Infection by drug resistant tubercle bacilli in Poland. Tubercle 1962; 43: 382-385. 27. Leowski J, Rudzińska H: Thirty years of tuberculosis control In Poland. Polish Medi.Publ., Warsaw 1975. 28. Augustynowicz-Kopeć E: Gručlica lekooporna w Polsce. Analiza epidemiologiczna, mikrobiologiczna i genetyczna. Rozprawa habilitacyjna. 2007. 29. WHO Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Report No. 3. 1999-2002. Geneva 2004, WHO/HTM/TB/2004.343. 30. Anon. The tuberculosis X factor. Lancet Infect. Dis. 2006; 6: 11, 679-679.

otrzymano/received: 2009-02-25
zaakceptowano/accepted: 2009-03-27

Adres/address:
*Ewa Augustynowicz-Kopeć
Zakład Mikrobiologii, Krajowe Referencyjne Laboratorium Prątka
ul. Płocka 26, 01-138 Warszawa
tel.: (0-22) 431-21-82
e-mail: e.kopec@igichp.edu.pl

Pełna wersja artykułu Gruźlica lekooporna w Polsce dostępna w Czytelni Medycznej Borgis.

Copyright © Wydawnictwo Medyczne Borgis Sp. z o.o. 2007-2013
Chcesz być na bieżąco? Polub nas na Facebooku: strona Wydawnictwa na Facebooku